Latest Breaking News On - Cablon medical - Page 1 : comparemela.com

AGA Reading Room | Marjolijn Duijvestein on Tofacitinib Over Vedolizumab for Ulcerative Colitis

Clinicians often face uncertainty in deciding when and how to position biologics versus Janus kinase (JAK) inhibitors in anti-tumor necrosis factor (TNF) therapy-refractory patients with ulcerative colitis (UC). To shed light on this dilemma, Marjolijn Duijvestein, MD, of Amsterdam University Medical Center in the Netherlands, and colleagues compared the relative effectiveness and safety of vedolizumab (Entyvio) and the JAK inhibitor tofacitinib (Xeljanz) in anti-TNF-exposed UC patients in the Dutch Initiative on Crohn and Colitis (ICC) Registry.

Noord hollandFalk pharmaClin gastroenterol hepatolMarjolijn duijvesteinTillotts pharmaRobarts clinical trials incInitiative on crohnAmsterdam university medical centerDutch initiative on crohnDutch initiativeClinical gastroenterologyCablon medicalEcho pharmaRobarts clinical trialsGastroenterol hepatol

Exclusive Distribution Agreement from Acceletronics Inc with Cablon Medical CNERGY Total Body Irradiation, TBI for Linear Accelerators

Exclusive Distribution Agreement from Acceletronics Inc with Cablon Medical CNERGY Total Body Irradiation, TBI for Linear Accelerators
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.

United statesDavid chicatelliSee campaignVarian medical systemsAcceletronics incElekta solutionsCablon medicalPalo altoNorth americaLarry dayRadiation physicistRadiation therapistRadiation oncologistGeneral electricLinear acceleratorRadiation oncology

Exclusive Distribution Agreement from Acceletronics Inc with Cablon Medical CNERGY Total Body Irradiation, TBI for Linear Accelerators – Business

iCrowdNewswire Jan 25, 2021 11:00 AM ET Exton, PA: Acceletronics Inc., today announced its exclusive distribution agreement with Cablon Medical, The Netherlands, for their new CNERGY radiotherapy solutions. Total body radiation therapy can be a complex treatment for the end user. CNERGY TBI alleviates many of the roadblocks that increase the time a patient is in the treatment room and allows real time image verification for clinicians. CNERGY TBI answers todays clinical demand for increased patient safety and treatment accuracy. The CNERGY platform compliment cancer treatments when used with a linear accelerator (LINAC), like those made by Varian Medical Systems, Palo Alto, CA and Elekta Solutions AB, Stockholm, Sweden.

United statesDavid chicatelliVarian medical systemsAcceletronics incElekta solutionsCablon medicalPalo altoNorth americaLarry dayRadiation physicistRadiation therapistRadiation oncologistGeneral electricLinear acceleratorCancer careRadiation oncology